ScyFIX's Convertible Note Round

ScyFIX raised a round of funding on July 26, 2007.

ScyFIX uses targeted micro-current energy to address the Dry form of Macular Degeneration (AMD) and Retinitis Pigmentosa (RP). ScyFIX has completed two human Pilot clinical trials for RP and AMD that …

Articles about ScyFIX's Convertible Note Round: